Clinical Trial Update: Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating camrelizumab with pirfenidone and chemotherapy for advanced triple-negative breast cancer; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Harbin Medical University | Conditions: Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING